Unicycive Therapeutics, Inc. (NASDAQ: UNCY) reported Q2 EPS of ($1.50), $1.43 worse than the analyst estimate of ($0.07).

For earnings history and earnings-related data on Unicycive Therapeutics, Inc. (UNCY) click here.